Vivace Closes $30 Million Round for Novel Hippo Pathway Oncology Therapies
publication date: Dec 16, 2020
Vivace Therapeutics, a San Francisco area biotech, closed a $30 million Series C financing to develop novel oncology therapies that target the Hippo pathway. Vivace is led by Sofie Qiao, PhD, who previously served as managing director at WuXi Ventures, which supported the company in earlier rounds along with other China investors. The company expects to start clinical trials of its lead candidate in early 2021, targeting tumors dependent on activated YAP. The Series C round was led by Boxer Capital and joined by new investor RA Capital Management alongside existing investor Canaan Partners. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.